Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Morris

Showing results (271-280 of 303) with videos related to

Pageof 31
Sort By:
Plos Pathogens|August 29, 2018
Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7Sakaorat Lertjuthaporn, Claudia Cicala, Donald Van Ryk, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2006
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependentJoke Snoeck, Rami Kantor, Robert W Shafer, et al.
Journal of Virology|October 10, 2008
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremiaGeorgia D Tomaras, Nicole L Yates, Pinghuang Liu, et al.
PLOS Global Public Health|September 20, 2024
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trialVimla Naicker, Fatima Laher, Linda-Gail Bekker, et al.
Biorxiv : the Preprint Server for Biology|January 5, 2021
Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functionsAndrea R Shiakolas, Kevin J Kramer, Daniel Wrapp, et al.
Plos Medicine|May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trialsZoe Moodie, Stephen R Walsh, Fatima Laher, et al.
Cell Reports. Medicine|May 31, 2021
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functionsAndrea R Shiakolas, Kevin J Kramer, Daniel Wrapp, et al.
Immunity|December 20, 2014
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conservedKevin Wiehe, David Easterhoff, Kan Luo, et al.
Nature Communications|December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Journal of Virology|October 16, 2015
New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional PotencyNicole A Doria-Rose, Jinal N Bhiman, Ryan S Roark, et al.
Pageof 31

Showing results (271-280 of 303) with videos related to

Sort By:
Pageof 31
Plos Pathogens|August 29, 2018
Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7Sakaorat Lertjuthaporn, Claudia Cicala, Donald Van Ryk, et al.
Antimicrobial Agents and Chemotherapy|January 27, 2006
Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependentJoke Snoeck, Rami Kantor, Robert W Shafer, et al.
Journal of Virology|October 10, 2008
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremiaGeorgia D Tomaras, Nicole L Yates, Pinghuang Liu, et al.
PLOS Global Public Health|September 20, 2024
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trialVimla Naicker, Fatima Laher, Linda-Gail Bekker, et al.
Biorxiv : the Preprint Server for Biology|January 5, 2021
Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functionsAndrea R Shiakolas, Kevin J Kramer, Daniel Wrapp, et al.
Plos Medicine|May 23, 2020
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trialsZoe Moodie, Stephen R Walsh, Fatima Laher, et al.
Cell Reports. Medicine|May 31, 2021
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functionsAndrea R Shiakolas, Kevin J Kramer, Daniel Wrapp, et al.
Immunity|December 20, 2014
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conservedKevin Wiehe, David Easterhoff, Kan Luo, et al.
Nature Communications|December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trialsDaniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Journal of Virology|October 16, 2015
New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional PotencyNicole A Doria-Rose, Jinal N Bhiman, Ryan S Roark, et al.
Pageof 31